32 results
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
7 May 24
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
4:05pm
due to a decrease in employee related costs, partially offset by an increase in third party expenses. Total R&D stock-based compensation expense
8-K
EX-99.1
ALGS
Aligos Therapeutics Inc
12 Mar 24
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
4:06pm
and ASO programs in 2022, partially offset by increases in our ongoing activities and related expenditures associated with our CAM clinical trial … and patent attorney costs, partially offset by a decrease in facility expenses. Total G&A stock-based compensation expense incurred for the year ended
8-K
EX-99.1
z0s dudowoa8u
2 Nov 23
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
9kxy4thk5ialto
3 Aug 23
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
kwq t75mez0cwtgtd2g
4 May 23
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
ld0c89mg48p hfzqcrz6
4 Aug 22
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
ypdfrd337yrv1j
4 May 22
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2022 Financial Results
4:06pm
424B4
qomwhm9d257elv
1 Jul 21
Prospectus supplement with pricing info
4:31pm